Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P. Marmé F, et al. Among authors: altevogt p. Int J Cancer. 2012 Aug 15;131(4):E586-91. doi: 10.1002/ijc.27329. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22034009
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Among authors: altevogt p. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
CD24 polymorphisms in breast cancer: impact on prognosis and risk.
Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jäger D, Flesch-Janys D, Chang-Claude J, Marmé F. Buck K, et al. Among authors: altevogt p. Breast Cancer Res Treat. 2013 Feb;137(3):927-37. doi: 10.1007/s10549-012-2325-9. Epub 2013 Jan 13. Breast Cancer Res Treat. 2013. PMID: 23314606
Linking L1CAM-mediated signaling to NF-κB activation.
Kiefel H, Pfeifer M, Bondong S, Hazin J, Altevogt P. Kiefel H, et al. Among authors: altevogt p. Trends Mol Med. 2011 Apr;17(4):178-87. doi: 10.1016/j.molmed.2010.11.005. Epub 2010 Dec 30. Trends Mol Med. 2011. PMID: 21195665 Review.
L1CAM: a major driver for tumor cell invasion and motility.
Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P. Kiefel H, et al. Among authors: altevogt p. Cell Adh Migr. 2012 Jul-Aug;6(4):374-84. doi: 10.4161/cam.20832. Epub 2012 Jul 1. Cell Adh Migr. 2012. PMID: 22796939 Free PMC article. Review.
248 results